Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Brigham and Women's Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
739
Shown on this page
12
Current sort
Recently updated
Campus scope
Brigham and Women's Hospital, Boston, MA
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Brigham and Women's Hospital, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 229–240 of 739 matching trials with a site at Brigham and Women's Hospital, Boston, MA.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

NCT05538130
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Brain Neoplasms, Differentiated Thyroid Cancer, Glioma, HGG, High Grade Glioma, LGG, Low Grade Glioma, Malignant Neoplasms, Melanoma, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, Thyroid Cancer
Interventions
PF-07799544, PF-07799933
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 13, 2026, 10:44 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT05355701
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Colorectal Cancer (Part 1), Glioma, Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer
Interventions
PF-07799933, binimetinib, cetuximab, fluorouracil, leucovorin, midazolam, oxaliplatin
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
31
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 17, 2026, 5:08 PM EDT
Not yet recruiting Phase 1 Interventional

Repurposing a Combination Antiretroviral Drug Therapy to Target Retrotransposons and Treat Early Alzheimer's Disease

NCT07795307
Site status not listed — check the official record
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Emtricitabine and tenofovir disoproxil fumarate combination, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 16, 2026, 3:36 PM EDT
Recruiting Phase 2 Interventional

Toripalimab With Chemotherapy for Sinus Cancer

NCT06940180
Status at this site: Recruiting
View directory record Official record
Conditions
Locally Advanced Head and Neck Cancer, Paranasal Sinus Neoplasms, Sinonasal Cancer, Sinonasal Undifferentiated Carcinoma, Squamous Cell Carcinoma
Interventions
Carboplatin, Cisplatin, Docetaxel, Radiation Therapy, Toripalimab
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 14, 2026, 7:02 PM EDT
Recruiting Not applicable Interventional

Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia

NCT04839614
Status at this site: Recruiting
View directory record Official record
Conditions
EIN, Endometrial Cancer Stage I, Endometrial Carcinoma, Endometrial Intraepithelial Neoplasia, Obesity
Interventions
CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 13, 2026, 3:09 PM EDT
Active, not recruiting Phase 3 Interventional

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

NCT01901094
Site status not listed — check the official record
View directory record Official record
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
Axillary Lymph Node Dissection (ALND), Axillary Radiation Therapy, Nodal Radiation Therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1228
States / cities
Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 730 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 15, 2026, 3:05 AM EDT
Recruiting Phase 1 Interventional

CIML NK Cells With Venetoclax for AML

NCT06152809
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid
Interventions
Cytokine-Induced Memory-like Natural Killer Cells, Interleukin-2, Venetoclax
Biological · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 14, 2026, 4:43 PM EDT
Active, not recruiting Not applicable Interventional

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

NCT06096337
Site status not listed — check the official record
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone, FARAPULSE™ Pulsed Field Ablation (PFA) System
Drug · Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 15, 2026, 10:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

NCT03055013
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Unclassified Renal Cell Carcinoma
Interventions
Nephrectomy, Nivolumab, Patient Observation, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
396
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 293 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 2, 2026, 8:18 PM EDT
Active, not recruiting Phase 2 Interventional

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

NCT02849496
Site status not listed — check the official record
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography, Questionnaire Administration, X-Ray Imaging
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 14, 2026, 5:14 AM EDT
Recruiting Not applicable Interventional

The Glaucoma and Retinopathy Screening Study

NCT06882356
Status at this site: Recruiting
View directory record Official record
Conditions
Glaucoma
Interventions
AI-based glaucoma screening, IOP measurement, Virtual Reality Visual Field Testing
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
7
States / cities
Boston, Massachusetts • Chelsea, Massachusetts • Lynn, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 16, 2026, 10:40 PM EDT
Recruiting Not applicable Interventional

BRIDGE-SIC Efficacy Trial

NCT07735442
Status at this site: Recruiting
View directory record Official record
Conditions
Cancer
Interventions
LLM-generated SIC summary email to clinical teams
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 13, 2026, 11:11 PM EDT

About this Brigham and Women's Hospital institution page

What this page lists
ClinicalTrials.gov records that list Brigham and Women's Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.